Supplementary Material

Multiomics-Identified Intervention to Restore Ethanol-Induced Dysregulated Proteostasis and Secondary Sarcopenia in Alcoholic Liver Disease

Shashi Shekhar Singh^a Avinash Kumar^a Nicole Welch^{a,b} Jinendiran Sekar^a Saurabh Mishra^a Annette Bellar^a Mahesha Gangadhariah^a Amy Attaway^{a,c} Hayder Al Khafaji^b Xiaoqin Wu^a Vai Pathak^a Vandana Agrawal^a Megan R. McMullen^a Troy A. Hornberger^d Laura E. Nagy^a Gangarao Davuluri^e Srinivasan Dasarathy^{a,b}

^aDepartment of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH, USA, ^bDepartment of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA, ^cDepartment of Pulmonology, Cleveland Clinic, Cleveland, OH, USA, ^dDepartment of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA, ^ePennington Biomedical Research Center, Baton Rouge, LA, USA



Supplementary Figure 1. Schematic of approach. Using a complementary bioinformatics and experimental approach, HMB was identified as a mechanism based therapeutic for sarcopenia in alcohol-related liver disease. EtOH 100 mM ethanol; mALD mouse model of alcohol related liver disease; PF pair-fed mice; UnT untreated.



Supplementary Figure 2. Metabolism of branched chain amino acids. Pathways of branched chain amino

acid metabolism in the skeletal muscle and generation of $\beta\mbox{-hydroxybutyrate}$ in the cytosol.

Supplementary Fig. 3. Identification of HMB as a regulatory molecule. Manual curation of different pathways and molecular responses to published anabolic metabolites show HMB targets ethanol-induced perturbations.

Supplementary Tables

Due to their size, please use the following links to download and access the Supplementary Tables:

Supplementary Table 1: List of Antibodies used in HMB study. https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 1.xlsx

Supplementary Table 2: C2C12 transcriptomic heatmap NW. https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 2.xlsx

Supplementary Table 3: RNAseq cell mtorc pathway NW. https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 3.xlsx

Supplementary Table 4: Proteomics C2C12 mtorc pathway NW. https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary_Table_4.xlsx

Supplementary Table 5: IGF-1 6h EtOH v UnT RNAseq pathway NW. https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 5.xlsx

Supplementary Table 6: Ubiquitination heatmap NW. <u>https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 6.xlsx</u>

Supplementary Table 7: gProfiler_mmusculus NW. https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 7.xlsx

Supplementary Table 8: Open Targets Venn Diagram NW. <u>https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 8.xlsx</u>

Supplementary Table 9: Mouse RNAseq Bar Graph NW. <u>https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 9.xlsx</u>

Supplementary Table 10: BCAT data 8-10-20. https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary_Table_10.xlsx

Supplementary Table 11: Biosynthesis muscle AA Table new 08-03-20 NW. <u>https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 11.docx</u>

Supplementary Table 12: Degradation muscle AA Table new 08-03-20 NW. <u>https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 12.docx</u>

Supplementary Table 13: Biosynthesis liver AA Table new 08-03-20 NW. https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 13.docx

Supplementary Table 14: Degradation liver AA Table new 08-03-20 NW. <u>https://www.cellphysiolbiochem.com/Articles/000327/SM/Supplementary Table 14.docx</u>